Cancer Stem Cell for Tumor Therapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Oct 13

PMID 34638298

Citations 16

Authors

Binjie Huang

Xin Yan

Yumin Li

Affiliations

Soon will be listed here.

Abstract

Tumors pose a significant threat to human health. Although many methods, such as operations, chemotherapy and radiotherapy, have been proposed to eliminate tumor cells, the results are unsatisfactory. Targeting therapy has shown potential due to its specificity and efficiency. Meanwhile, it has been revealed that cancer stem cells (CSCs) play a crucial role in the genesis, development, metastasis and recurrence of tumors. Thus, it is feasible to inhibit tumors and improve prognosis via targeting CSCs. In this review, we provide a comprehensive understanding of the biological characteristics of CSCs, including mitotic pattern, metabolic phenotype, therapeutic resistance and related mechanisms. Finally, we summarize CSCs targeted strategies, including targeting CSCs surface markers, targeting CSCs related signal pathways, targeting CSC niches, targeting CSC metabolic pathways, inducing differentiation therapy and immunotherapy (tumor vaccine, CAR-T, oncolytic virus, targeting CSCs-immune cell crosstalk and immunity checkpoint inhibitor). We highlight the potential of immunity therapy and its combinational anti-CSC therapies, which are composed of different drugs working in different mechanisms.

Citing Articles

Anticancer role of flubendazole: Effects and molecular mechanisms (Review).

Xing X, Zhou Z, Peng H, Cheng S Oncol Lett. 2024; 28(6):558.

PMID: 39355784 PMC: 11443308. DOI: 10.3892/ol.2024.14691.

Exploring the interplay of natural products and long non-coding RNAs in colorectal cancer: pathogenesis, diagnosis, and overcoming drug resistance.

Elimam H, Eldeib M, Kizilaslan E, Alhamshry N, Ashour A, Elfar N Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1243-1263.

PMID: 39287672 DOI: 10.1007/s00210-024-03425-9.

Cellular and Molecular Mechanisms of Chemoresistance for Gastric Cancer.

Li Z, Shu X, Liu X, Li Q, Hu Y, Jia B Int J Gen Med. 2024; 17:3779-3788.

PMID: 39224691 PMC: 11368108. DOI: 10.2147/IJGM.S473749.

Cheminformatics-based identification of phosphorylated RET tyrosine kinase inhibitors for human cancer.

Talukder M, Aktaruzzaman M, Siddiquee N, Islam S, Wani T, Alkahtani H Front Chem. 2024; 12:1407331.

PMID: 39086985 PMC: 11289668. DOI: 10.3389/fchem.2024.1407331.

E2F1 Facilitates the Proliferation and Stemness of Gastric Cancer Cells by Activating CDC25B Transcription and Modulating the MAPK Pathway.

Liu M, Xu C, Cheng G, Chen Z, Pan X, Mei Y Biochem Genet. 2024; .

PMID: 38981987 DOI: 10.1007/s10528-024-10864-9.

References

Beck B, Driessens G, Goossens S, Youssef K, Kuchnio A, Caauwe A . A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature. 2011; 478(7369):399-403. DOI: 10.1038/nature10525. View

Huynh L, Hipolito C, Ten Dijke P . A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment. Biomolecules. 2019; 9(11). PMC: 6921009. DOI: 10.3390/biom9110743. View

Deshmukh A, Arfuso F, Newsholme P, Dharmarajan A . Regulation of Cancer Stem Cell Metabolism by Secreted Frizzled-Related Protein 4 (sFRP4). Cancers (Basel). 2018; 10(2). PMC: 5836072. DOI: 10.3390/cancers10020040. View

Lee S, Moon J, Redman B, Chidiac T, Flaherty L, Zha Y . Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2014; 121(3):432-440. PMC: 4304973. DOI: 10.1002/cncr.29055. View

Li M, Knight D, Smyth M, Stewart T . Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways. Cancer Immunol Immunother. 2012; 61(8):1255-68. PMC: 11029674. DOI: 10.1007/s00262-012-1200-1. View

Shaik N, Hee B, Liang Y, LaBadie R . Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers. Clin Pharmacol Drug Dev. 2019; 8(7):895-902. PMC: 6850403. DOI: 10.1002/cpdd.692. View

Thurston G, Noguera-Troise I, Yancopoulos G . The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer. 2007; 7(5):327-31. DOI: 10.1038/nrc2130. View

Wang K, Zhang T, Dong Q, Nice E, Huang C, Wei Y . Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death Dis. 2013; 4:e537. PMC: 3613828. DOI: 10.1038/cddis.2013.50. View

Bhuria V, Xing J, Scholta T, Bui K, Nguyen M, Malek N . Hypoxia induced Sonic Hedgehog signaling regulates cancer stemness, epithelial-to-mesenchymal transition and invasion in cholangiocarcinoma. Exp Cell Res. 2019; 385(2):111671. DOI: 10.1016/j.yexcr.2019.111671. View

10.

Fang D, Kim Y, Lee C, Aggarwal S, McKinnon K, Mesmer D . Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer. 2010; 102(8):1265-75. PMC: 2855999. DOI: 10.1038/sj.bjc.6605610. View

11.

Takaishi S, Okumura T, Tu S, Wang S, Shibata W, Vigneshwaran R . Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009; 27(5):1006-20. PMC: 2746367. DOI: 10.1002/stem.30. View

12.

Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C . Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov. 2014; 4(10):1154-67. PMC: 4184927. DOI: 10.1158/2159-8290.CD-13-0830. View

13.

Reid S, Pockley A . Cytokine regulation of CD44 expression on rat intestinal epithelial cells. Immunol Invest. 2000; 29(3):271-86. DOI: 10.3109/08820130009060867. View

14.

Cai X, Yao Z, Li L, Huang J . Role of DKK4 in Tumorigenesis and Tumor Progression. Int J Biol Sci. 2018; 14(6):616-621. PMC: 6001654. DOI: 10.7150/ijbs.24329. View

15.

Fendler A, Bauer D, Busch J, Jung K, Wulf-Goldenberg A, Kunz S . Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun. 2020; 11(1):929. PMC: 7026425. DOI: 10.1038/s41467-020-14700-7. View

16.

Hoey T, Yen W, Axelrod F, Basi J, Donigian L, Dylla S . DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 2009; 5(2):168-77. DOI: 10.1016/j.stem.2009.05.019. View

17.

Zhao J . Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther. 2016; 160:145-58. PMC: 4808328. DOI: 10.1016/j.pharmthera.2016.02.008. View

18.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

19.

Chen P, Hsu W, Han J, Xia Y, DePinho R . Cancer Stemness Meets Immunity: From Mechanism to Therapy. Cell Rep. 2021; 34(1):108597. PMC: 7839836. DOI: 10.1016/j.celrep.2020.108597. View

20.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View